PRGO logo

Perrigo Company plc

PRGO
Healthcare|Drug Manufacturers - Specialty & Generic|IE
$15.85
+0.14 (+0.89%)
DCF Value
$78.08
Cash / Share
$3.13

About

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Stock Price

+6.2%(1Y)
1M
+9.3%
3M
+23.4%
6M
+35.4%
YTD
+13.9%
1Y
+11.2%
3Y
-45.4%
5Y
-66.9%

Pipeline Summary

10 total trials
7
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
Completed: 7Unknown: 2Terminated: 1

Key Facts

Market Cap$2.20B
Employees8,100 (-3% YoY)
CEOAlbert A. Manzone
IPO DateDec 17, 1991
Beta0.54
52-Week Range$9.23 – $16.81
Avg Volume2,760,355
ExchangeNYSE

Ownership

Float99.5%
Shares Outstanding138.8M

Recent Insider Trades

Parker Geoffrey M.OPTION EX.
Sep 11, 20261,263 shares @ $13.66
Parker Geoffrey M.TAX W/H
Sep 11, 2026607 shares @ $13.66
Parker Geoffrey M.OPTION EX.
Sep 11, 20261,263 shares
Alford Bradley AOPTION EX.
Sep 11, 20261,263 shares @ $13.66
Alford Bradley ATAX W/H
Sep 11, 2026607 shares @ $13.66

Peers

ATECAlphatec Holdings, Inc.
$1.15B
BHCBausch Health Companies Inc.
$3.06B
FOLDAmicus Therapeutics, Inc.
$4.55B
HCMHUTCHMED (China) Limited
$2.64B
HTFLHeartflow, Inc. Common Stock
$4.56B
LIVNLivaNova PLC
$4.96B
SGRYSurgery Partners, Inc.
$2.99B
SRRKScholar Rock Holding Corporation
$5.72B
Data last updated: Nov 9, 2026, 04:29 AM